FDA approves label changes for antimalarial drug mefloquine hydrochloride due to risk of serious psychiatric and nerve side effects
Posted by
The Nurse Practitioners of New York
on
Manhattan, NY
Please CLICK HERE to view the Drug Safety Communication
Source: FDA